Skip to main content
Premium Trial:

Request an Annual Quote

The New Monolith

Pfizer unveils what the company's structure will look like after it swallows up Wyeth. According to the Wall Street Journal, Pfizer will be splitting its research and development efforts in two: the small molecule section will be overseen by Pfizer's current R&D chief Martin Mackay, and the biologic section will be led by Wyeth's R&D chief Mikael Dolsten. "Creating two distinct, but complementary, research organizations, led by the top scientist from each company, will provide sharper focus, less bureaucracy and clearer accountability in drug discovery," Pfizer CEO Jeffrey Kindler said in a news release.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.